Literature DB >> 24231236

Dose/volume-response relations for rectal morbidity using planned and simulated motion-inclusive dose distributions.

Maria Thor1, Aditya Apte, Joseph O Deasy, Àsa Karlsdóttir, Vitali Moiseenko, Mitchell Liu, Ludvig Paul Muren.   

Abstract

BACKGROUND AND
PURPOSE: Many dose-limiting normal tissues in radiotherapy (RT) display considerable internal motion between fractions over a course of treatment, potentially reducing the appropriateness of using planned dose distributions to predict morbidity. Accounting explicitly for rectal motion could improve the predictive power of modelling rectal morbidity. To test this, we simulated the effect of motion in two cohorts.
MATERIALS AND METHODS: The included patients (232 and 159 cases) received RT for prostate cancer to 70 and 74 Gy. Motion-inclusive dose distributions were introduced as simulations of random or systematic motion to the planned dose distributions. Six rectal morbidity endpoints were analysed. A probit model using the QUANTEC recommended parameters was also applied to the cohorts.
RESULTS: The differences in associations using the planned over the motion-inclusive dose distributions were modest. Statistically significant associations were obtained with four of the endpoints, mainly at high doses (55-70 Gy), using both the planned and the motion-inclusive dose distributions, primarily when simulating random motion. The strongest associations were observed for GI toxicity and rectal bleeding (Rs=0.12-0.21; Rs=0.11-0.20). Applying the probit model, significant associations were found for tenesmus and rectal bleeding (Rs=0.13, p=0.02).
CONCLUSION: Equally strong associations with rectal morbidity were observed at high doses (>55 Gy), for the planned and the simulated dose distributions including in particular random rectal motion. Future studies should explore patient-specific descriptions of rectal motion to achieve improved predictive power. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Morbidity; Organ motion; Prostate cancer; Radiotherapy; Rectum

Mesh:

Year:  2013        PMID: 24231236      PMCID: PMC4765373          DOI: 10.1016/j.radonc.2013.10.021

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  27 in total

1.  CERR: a computational environment for radiotherapy research.

Authors:  Joseph O Deasy; Angel I Blanco; Vanessa H Clark
Journal:  Med Phys       Date:  2003-05       Impact factor: 4.071

2.  The dose-response of the anal sphincter region--an analysis of data from the MRC RT01 trial.

Authors:  Florian Buettner; Sarah L Gulliford; Steve Webb; Matthew R Sydes; David P Dearnaley; Mike Partridge
Journal:  Radiother Oncol       Date:  2012-04-18       Impact factor: 6.280

3.  Dose response explorer: an integrated open-source tool for exploring and modelling radiotherapy dose-volume outcome relationships.

Authors:  I El Naqa; G Suneja; P E Lindsay; A J Hope; J R Alaly; M Vicic; J D Bradley; A Apte; J O Deasy
Journal:  Phys Med Biol       Date:  2006-10-19       Impact factor: 3.609

4.  Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer.

Authors:  Stephanie T H Peeters; Joos V Lebesque; Wilma D Heemsbergen; Wim L J van Putten; Annerie Slot; Michel F H Dielwart; Peter C M Koper
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-01-18       Impact factor: 7.038

5.  Parameters for the Lyman Kutcher Burman (LKB) model of Normal Tissue Complication Probability (NTCP) for specific rectal complications observed in clinical practise.

Authors:  Sarah L Gulliford; Mike Partridge; Matthew R Sydes; Steve Webb; Philip M Evans; David P Dearnaley
Journal:  Radiother Oncol       Date:  2011-11-25       Impact factor: 6.280

6.  LENT SOMA tables.

Authors: 
Journal:  Radiother Oncol       Date:  1995-04       Impact factor: 6.280

7.  Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)

Authors:  J D Cox; J Stetz; T F Pajak
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-03-30       Impact factor: 7.038

Review 8.  Faecal incontinence following radiotherapy for prostate cancer: a systematic review.

Authors:  Yasuko Maeda; Morten Høyer; Lilli Lundby; Christine Norton
Journal:  Radiother Oncol       Date:  2011-01-21       Impact factor: 6.280

9.  Testing the new ICRU 62 'Planning Organ at Risk Volume' concept for the rectum.

Authors:  Ludvig Paul Muren; Asa Karlsdottir; Yngve Kvinnsland; Tore Wentzel-Larsen; Olav Dahl
Journal:  Radiother Oncol       Date:  2005-06       Impact factor: 6.280

10.  Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy.

Authors:  Mitchell Liu; Tom Pickles; Alexander Agranovich; Eric Berthelet; Graeme Duncan; Mira Keyes; Winkle Kwan; Michael McKenzie; James Morris; Howard Pai; Scott Tyldesley; Jonn Wu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-01-01       Impact factor: 7.038

View more
  10 in total

1.  Comparison of different contouring definitions of the rectum as organ at risk (OAR) and dose-volume parameters predicting rectal inflammation in radiotherapy of prostate cancer: which definition to use?

Authors:  Mirko Nitsche; Werner Brannath; Matthias Brückner; Dirk Wagner; Alexander Kaltenborn; Nils Temme; Robert M Hermann
Journal:  Br J Radiol       Date:  2016-12-12       Impact factor: 3.039

2.  Influence of image slice thickness on rectal dose-response relationships following radiotherapy of prostate cancer.

Authors:  C Olsson; M Thor; M Liu; V Moissenko; S E Petersen; M Høyer; A Apte; J O Deasy
Journal:  Phys Med Biol       Date:  2014-06-17       Impact factor: 3.609

3.  Advancing our quantitative understanding of radiotherapy normal tissue morbidity.

Authors:  Joseph O Deasy; Ludvig P Muren
Journal:  Acta Oncol       Date:  2014-05       Impact factor: 4.089

4.  Spatial rectal dose/volume metrics predict patient-reported gastro-intestinal symptoms after radiotherapy for prostate cancer.

Authors:  Oscar Casares-Magaz; Ludvig Paul Muren; Vitali Moiseenko; Stine E Petersen; Niclas Johan Pettersson; Morten Høyer; Joseph O Deasy; Maria Thor
Journal:  Acta Oncol       Date:  2017-09-08       Impact factor: 4.089

5.  Prediction of gastrointestinal toxicity after external beam radiotherapy for localized prostate cancer.

Authors:  Vittoria D'Avino; Giuseppe Palma; Raffaele Liuzzi; Manuel Conson; Francesca Doria; Marco Salvatore; Roberto Pacelli; Laura Cella
Journal:  Radiat Oncol       Date:  2015-04-08       Impact factor: 3.481

6.  Prostate external beam radiotherapy combined with high-dose-rate brachytherapy: dose-volume parameters from deformably-registered plans correlate with late gastrointestinal complications.

Authors:  Calyn R Moulton; Michael J House; Victoria Lye; Colin I Tang; Michele Krawiec; David J Joseph; James W Denham; Martin A Ebert
Journal:  Radiat Oncol       Date:  2016-10-31       Impact factor: 3.481

7.  Dosimetry and Gastrointestinal Toxicity Relationships in a Phase II Trial of Pelvic Lymph Node Radiotherapy in Advanced Localised Prostate Cancer.

Authors:  M R Ferreira; K Thomas; L Truelove; A Khan; C Parker; D P Dearnaley; S Gulliford
Journal:  Clin Oncol (R Coll Radiol)       Date:  2019-03-20       Impact factor: 4.126

8.  Salvage radiation therapy in prostate cancer: relationship between rectal dose and long-term, self-reported rectal bleeding.

Authors:  K Braide; J Kindblom; U Lindencrona; J Hugosson; N Pettersson
Journal:  Clin Transl Oncol       Date:  2020-07-03       Impact factor: 3.405

9.  Registering prostate external beam radiotherapy with a boost from high-dose-rate brachytherapy: a comparative evaluation of deformable registration algorithms.

Authors:  Calyn R Moulton; Michael J House; Victoria Lye; Colin I Tang; Michele Krawiec; David J Joseph; James W Denham; Martin A Ebert
Journal:  Radiat Oncol       Date:  2015-12-14       Impact factor: 3.481

10.  Ano-rectal wall dose-surface maps localize the dosimetric benefit of hydrogel rectum spacers in prostate cancer radiotherapy.

Authors:  Ben G L Vanneste; Florian Buettner; Michael Pinkawa; Philippe Lambin; Aswin L Hoffmann
Journal:  Clin Transl Radiat Oncol       Date:  2018-11-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.